Spots Global Cancer Trial Database for FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Official Title: A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Study ID: NCT04551885
Conditions
Study Description
Brief Summary: This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Fate Trial Disclosure
Affiliation: Fate Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
